Literature DB >> 15785929

Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings.

José Garnacho-Montero1, C Ortiz-Leyba, Esteban Fernández-Hinojosa, Teresa Aldabó-Pallás, Aurelio Cayuela, Juan A Marquez-Vácaro, Andrés Garcia-Curiel, F J Jiménez-Jiménez.   

Abstract

OBJECTIVE: To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes. DESIGN AND
SETTING: All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively. PATIENTS: Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens. MEASUREMENTS AND
RESULTS: The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).
CONCLUSIONS: Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785929     DOI: 10.1007/s00134-005-2598-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  32 in total

1.  Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii.

Authors:  J Gómez; E Simarro; V Baños; L Requena; J Ruiz; F García; M Canteras; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-05       Impact factor: 3.267

2.  Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia.

Authors:  C M Luna; A Videla; J Mattera; C Vay; A Famiglietti; P Vujacich; M S Niederman
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

3.  Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii.

Authors:  B Mulin; D Talon; J F Viel; C Vincent; R Leprat; M Thouverez; Y Michel-Briand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

4.  Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia.

Authors:  H Dupont; H Mentec; J P Sollet; G Bleichner
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

5.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.

Authors:  M H Kollef; S Ward
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

6.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

7.  Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent.

Authors:  J Rello; M Rué; P Jubert; G Muses; R Soñora; J Vallés; M S Niederman
Journal:  Crit Care Med       Date:  1997-11       Impact factor: 7.598

8.  Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.

Authors:  David Landman; John M Quale; David Mayorga; Adedeyo Adedeji; Kalyani Vangala; Jayshree Ravishankar; Carlos Flores; Steven Brooks
Journal:  Arch Intern Med       Date:  2002-07-08

9.  Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology.

Authors:  D Villers; E Espaze; M Coste-Burel; F Giauffret; E Ninin; F Nicolas; H Richet
Journal:  Ann Intern Med       Date:  1998-08-01       Impact factor: 25.391

10.  Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia.

Authors:  Olivier Leroy; Agnès Meybeck; Thibaud d'Escrivan; Patrick Devos; Eric Kipnis; Hugues Georges
Journal:  Intensive Care Med       Date:  2003-09-12       Impact factor: 17.440

View more
  66 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Sepsis syndrome in Croatian intensive care units: piloting a national comparative clinical database.

Authors:  Vladimir Gasparović; Ivan Gornik; Dragutin Ivanović
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

Review 3.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

4.  Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

Authors:  Lisa A Kroeger; Laurie B Hovde; Isaac F Mitropoulos; Jeremy Schafer; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

5.  Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-17       Impact factor: 17.440

6.  Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study.

Authors:  V G Alexiou; A Michalopoulos; G C Makris; G Peppas; G Samonis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-28       Impact factor: 3.267

7.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

8.  Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agents.

Authors:  Ebru Cakir Edis; Osman N Hatipoglu; Ozlem Tansel; Necdet Sut
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

Review 9.  Acinetobacter infections: a growing threat for critically ill patients.

Authors:  M E Falagas; E A Karveli; I I Siempos; K Z Vardakas
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.